BACKGROUND: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of using CYP2C19 genotype-guided dual antiplatelet therapy (DAPT) selection in practice remains unclear.
D
ual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor is used after percutaneous coronary intervention (PCI) and an acute coronary syndrome (ACS) to prevent major adverse cardiovascular events. 1, 2 Clopidogrel remains the most commonly prescribed P2Y 12 inhibitor at most institutions, although alternative P2Y 12 inhibitors (prasugrel and ticagrelor) are widely available. 3, 4 Clopidogrel is a prodrug that requires biotransformation by CYP enzymes (cytochromes P450), most notably CYP2C19, to generate its active metabolite. CYP2C19 loss-of-function (LOF) polymorphisms are common and confer a reduced capacity for clopidogrel bioactivation and platelet inhibition. 5 Multiple retrospective analyses have demonstrated a significantly higher risk for major adverse cardiovascular events after PCI in clopidogreltreated patients carrying 1 (intermediate metabolizer, IM) or 2 (poor metabolizer, PM) CYP2C19 LOF alleles compared with clopidogrel-treated patients without a LOF allele. [6] [7] [8] [9] In contrast, CYP2C19 genotype does not alter the pharmacokinetics, antiplatelet effects, or clinical response to prasugrel or ticagrelor. 8, 10 These alternative P2Y 12 inhibitors have shown superior efficacy compared with clopidogrel in ACS patients after PCI in clinical trials 11, 12 but are more expensive and associated with an increased bleeding risk. 2, 13, 14 It remains unclear whether these effects are because of more potent or more consistent platelet inhibition. A secondary analysis of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction) suggested that the overall efficacy benefit conferred by prasugrel over clopidogrel was driven by the increased risk of major adverse cardiovascular events in CYP2C19 LOF allele carriers randomized to clopidogrel 6, 10, 15 ; however, the impact of CYP2C19 LOF alleles on the efficacy benefit of ticagrelor over clopidogrel in the PLATO study (Study of Platelet Inhibition and Patient Outcomes) was less dramatic. 8 Given the lack of prospective clinical outcome data, there remains considerable debate and uncertainty surrounding whether clinical CYP2C19 genetic testing should be routinely used to guide antiplatelet therapy selection in PCI patients. 1, 5, [16] [17] [18] Interest in genotypeguided antiplatelet therapy has been enhanced by a series of recent outcome-driven prospective studies, most notably a multicenter pragmatic investigation conducted by the IGNITE network (Implementing Genomics in Practice), which have suggested there is clinical benefit associated with using genotype-guided antiplatelet therapy. [19] [20] [21] [22] Thus, an increasing number of institutions are implementing CYP2C19 genetic testing, [23] [24] [25] despite limited data on the feasibility, sustainability, and clinical impact of using a CYP2C19 genotyping strategy to guide P2Y 12 inhibitor selection after PCI in real-world clinical practice. The University of North Carolina implemented an algorithm incorporating CYP2C19 genotyping in DAPT selection in 2012 26 ; therefore, the objectives of this study were to (1) determine the frequency of CYP2C19 testing and use of alternative therapy in CYP2C19 IMs and PMs over time, (2) identify the factors that influenced CYP2C19 testing and P2Y 12 inhibitor selection, and (3) examine the relationship between P2Y 12 inhibitor, CYP2C19 status, and clinical outcomes.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
CLINICAL PERSPECTIVE
CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after percutaneous coronary intervention (PCI). However, there remains considerable debate and uncertainty surrounding whether CYP2C19 genetic testing should be used clinically to guide antiplatelet therapy selection in PCI patients. The current investigation offers novel insight into the feasibility, sustainability, and clinical impact of using a CYP2C19 genotyping strategy to optimize P2Y 12 inhibitor selection after PCI in a real-world clinical setting. Results showed that CYP2C19 genotypes were frequently ordered, efficiently returned, and routinely used to guide P2Y 12 inhibitor selection after PCI over a 2-year period; however, the frequency of genotype testing and use of alternative therapy in CYP2C19 intermediate and poor metabolizers varied significantly over time. The current study also showed that use of clopidogrel in CYP2C19 intermediate and poor metabolizers was associated with a significantly higher risk of major adverse cardiovascular and cerebrovascular events compared with alternative therapy. Our results demonstrate that implementing a CYP2C19 genotype-guided antiplatelet therapy algorithm is feasible, sustainable, and associated with better clinical outcomes in a real-world clinical setting, but challenging to maintain at a consistently high level of fidelity. The clinical implications of our findings are that (1) clinicians need to be aware of the increased risk of major adverse cardiovascular or cerebrovascular associated with use of clopidogrel in PCI patients that carry either 1 or 2 copies of a CYP2C19 loss-of-function allele, and (2) genotypeguided selection of antiplatelet therapy, with use of alternative therapy in CYP2C19 intermediate and poor metabolizers, should be considered in high-risk patients undergoing PCI.
Study Design and Population
A clinical algorithm for CYP2C19 genotype-guided selection of antiplatelet therapy after PCI in high-risk patients (defined as ACS or high-risk coronary anatomy) was implemented at the University of North Carolina Cardiac Catheterization Laboratory in July 2012 ( Figure I in the Data Supplement), as described. 26 The CYP2C19 genotype test is ordered at the interventional cardiologist's discretion after risk stratification, and performed clinically on-site (Methods in the Data Supplement). Alternative antiplatelet therapy (prasugrel or ticagrelor) is recommended for CYP2C19 IMs and PMs, but the treatment decision is left to the discretion of the prescriber.
This single-center observational cohort study included 1193 consecutive adults ≥18 years of age who underwent PCI with coronary artery stent placement between July 1, 2012 and June 30, 2014 at the University of North Carolina Cardiac Catheterization Laboratory, and received DAPT with aspirin and a P2Y 12 inhibitor. The cohort includes 572 patients that underwent CYP2C19 genotyping during the index PCI admission between July 1, 2012 and December 31, 2013, and were included in the IGNITE network multicenter investigation of outcomes. 19 The investigation was approved by the University of North Carolina Biomedical Institutional Review Board. Because data collection was completed by retrospective review of the electronic health record (EHR), informed consent was not required.
Data Abstraction and Study End Points
Data were manually abstracted from the EHR. The primary implementation end point was P2Y 12 inhibitor maintenance therapy, which was defined as the agent prescribed over the course of follow-up after any changes in therapy. Key secondary end points included CYP2C19 genotype availability, initial P2Y 12 inhibitor therapy, and changes in therapy.
The primary clinical outcome was the composite of major adverse cardiovascular or cerebrovascular events (MACCE) over 12 months following the index PCI, which was defined as death, myocardial infarction, stent thrombosis, admission for ACS/unstable angina, ischemic cerebrovascular accident, or transient ischemic attack. A major secondary outcome was clinically significant bleeding, which was defined as a GUSTO (Global Use of Strategies to Open Occluded Arteries) moderate or severe/life-threatening bleeding event. 27 Events were identified using physician-reported diagnoses abstracted from the EHR and then verified by an interventional cardiologist.
Statistical Analysis
Data are presented as mean±SD, median (interquartile range), or count (%) unless otherwise indicated. To identify the key demographic and clinical factors associated with CYP2C19 testing and P2Y 12 inhibitor selection, associations were evaluated by logistic regression using univariate and multivariable models, and the odds ratio (OR) and 95% confidence intervals (CIs) for each covariate were calculated. Interaction and stratified analyses were also completed. The sustainability of algorithm use over time was assessed by comparing genotype and medication selection end points across consecutive 6-month time intervals during the study period (index PCI during July to December 2012, January to June 2013, July to December 2013, or January to June 2014) using χ 2 .
The relationship between CYP2C19 status, prescribed P2Y 12 inhibitor therapy, and the time to occurrence of the primary (MACCE) and secondary (clinically significant bleeding) clinical outcomes were evaluated using Cox proportional hazards regression in patients with follow-up available after the index PCI admission. Time-to-event analyses were completed after adjusting for covariates that differed across groups or were associated with the clinical outcome, and the adjusted hazard ratio and 95% CIs for each between-group comparison were calculated. Covariates included in the adjusted model for MACCE included sex, race, current smoker, history of atrial fibrillation, prior stent, elevated risk of bleeding, ACS indication for PCI; drug-eluting stent at index PCI, discharge angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, discharge β-blocker, and discharge statin. Covariates included in the adjusted model for bleeding included sex, race, elevated risk of bleeding, prior stent, ACS indication for PCI, and multiple vessels stented during index PCI. To determine whether CYP2C19 genotype modified the association between antiplatelet therapy and MACCE, the interaction between CYP2C19 phenotype (IM/PM or ultrarapid, rapid, or normal metabolizers) and antiplatelet therapy (clopidogrel or alternative) status was evaluated. Secondary analyses were completed in the strata of patients presenting with an ACS indication for their index PCI. Analyses were performed using SAS-JMP 12.0 and SAS 9.4 (SAS Institute, Cary, NC). P values <0.05 were considered statistically significant.
RESULTS

Study Population
This single-center observational cohort study included 1193 consecutive adults ≥18 years of age who underwent coronary artery stent placement between July 1, 2012 and June 30, 2014, and received DAPT. The mean age was 63±12 years, 67.6% were male, 20.7% were Black, and 53.8% underwent PCI for an ACS indication (Table 1) . On admission, 26.0% were receiving chronic P2Y 12 inhibitor therapy and 40.1% exhibited a risk factor for bleeding.
Genotype Testing
A CYP2C19 genotype was obtained in 868 (72.8%) patients ( Figure 1A ); of these, 794 (91.5%) were genotyped during the index admission. The median time from genotype order to result was 1 day, and 75% of results were available by the day after PCI. Among genotyped patients, 263 (30.2%) carried either 1 (IM) or 2 (PM) LOF alleles; 262 of which carried the *2 allele ( Figure 1B 
P2Y 12 Inhibitor Therapy Selection
Clopidogrel (69.4%) was the most commonly prescribed maintenance therapy with prasugrel (30.6%) and ticagrelor (3.3%) prescribed less frequently. Consistent with the algorithm, this distribution differed substantially by CYP2C19 phenotype status ( Figure 1C ). CYP2C19 IMs and PMs were routinely prescribed either prasugrel (59.9%) or ticagrelor (11.8%) as maintenance therapy, with 69.5% of IMs and 83.3% of PMs receiving alternative antiplatelet therapy. In contrast, clopidogrel was commonly prescribed in patients without a CYP2C19 LOF allele (76.4%) or without an available CYP2C19 genotype (88.9%).
Predictors of P2Y 12 Inhibitor Therapy Selection
Clinical factors associated with prasugrel/ticagrelor selection as the initial loading therapy during the index PCI are described in Table II CYP2C19 phenotype status also appeared to modify the association between certain clinical factors and antiplatelet therapy selection (Table IV in the Data Supplement). Although the association between ACS indication for PCI and prasugrel/ticagrelor selection was not modified by CYP2C19 phenotype status (Figure 2A) , the association between elevated bleeding risk and a lower likelihood of prescribing prasugrel/ ticagrelor was more pronounced in patients without a CYP2C19 LOF allele (OR, 0.20; 95% CI, 0.12-0.33) compared with IM/PMs (OR, 0.47; 95% CI, 0.27-0.81; interaction P=0.023; Figure 2B ). The association between left anterior descending artery stent placement and prasugrel/ticagrelor selection was only evident in patients without a LOF allele (interaction P=0.009; Figure 2C ).
Clinical Outcomes
Clinical outcomes were evaluated in 999 patients with follow-up available after the index PCI admission (83.7% of the study population). The median (interquartile range) time from index PCI to MACCE or last follow-up was 8.7 (4.4-11.1) months. During followup, 119 (11.9%; 18.9 per 100 patient-years) and 38 (3.8%; 6.1 per 100 patient-years) experienced MACCE and clinically significant bleeding events, respectively. Event frequencies were lower in the strata of patients that did not undergo CYP2C19 genotyping (Table 2) , which was expected because the algorithm only recommended genotyping in high-risk patients. The risk of developing MACCE was significantly associated with CYP2C19 phenotype and the prescribed antiplatelet therapy (Table 3) . Compared with CYP2C19 IM/PMs treated with alternative therapy, IM/ PMs treated with clopidogrel exhibited a significantly higher risk of MACCE (11.4 versus 52.0 events per 100 patient-years, respectively; Figure 3A ; adjusted hazard ratio, 4.65; 95% CI, 2.22-10.0; P<0.001). In contrast, no significant difference in MACCE was observed in CYP2C19 ultrarapid, rapid, or normal metabolizers treated with clopidogrel relative to alternative therapy (adjusted hazard ratio, 1.37; 95% CI, 0.72-2.85; P=0.347; CYP2C19*antiplatelet interaction P=0.018). There was no difference in risk of developing a clinically significant bleeding event across the CYP2C19 phenotype and antiplatelet therapy groups ( Figure 3B ; Table 3 ).
In patients with an ACS indication for their index PCI, the risk of MACCE was highest in the CYP2C19 IM/PMs treated with clopidogrel consistent with the overall study population ( Figure 3C ; Table V in the Data Supplement). Bleeding event rates were similar across the CYP2C19 phenotype and antiplatelet therapy groups in the ACS strata (Table V in the Data Supplement).
Sustainability of Genotype-Guided Antiplatelet Therapy Over Time
The frequency of CYP2C19 testing and use of alternative therapy in IM/PMs varied significantly throughout the study period. Following a very high rate of genotyping during the initial 6 months (88%), the proportion genotyped decreased during the subsequent 12 months (61% to 65%) and then increased (78%) during the final 6 months ( Figure 4A ). These differences were driven by the frequency of genotype testing during the index PCI admission (Table VI in the Data Supplement).
The frequent use of alternative therapy in CYP2C19 IM/PMs during the initial 6 months (83%) was sustained during the subsequent 6-month period but declined to 54% before increasing to 68% during the final 6 months ( Figure 4B ). This was accompanied by a significant decline in the proportion of IM/PMs that underwent a change in therapy from clopidogrel to alternative therapy (Table VI in the Data Supplement).
In contrast, no significant difference in alternative therapy use over time was observed in those without a CYP2C19 LOF allele ( Figure 4B ).
DISCUSSION
The current investigation evaluated use of CYP2C19 testing, P2Y 12 inhibitor selection and clinical outcomes following implementation of genotype-guided antiplatelet therapy over a 2-year period at a single academic medical center. Results showed that CYP2C19 genotypes were frequently ordered, efficiently returned, and routinely used to guide P2Y 12 inhibitor selection after PCI. The use of clopidogrel in CYP2C19 IM/PMs was associated with a significantly higher risk of MACCE compared with alternative therapy, consistent with results from the multicenter IGNITE network study. 19 The current study also demonstrates that the frequency of genotype testing at the time of PCI and use of alternative therapy in CYP2C19 IM/PMs varied significantly over time. Taken together, these data illustrate that implementing a CYP2C19-guided antiplatelet therapy algorithm is feasible, sustainable, and associated with better clinical outcomes in real-world clinical practice but challenging to maintain at a consistently high level of fidelity.
Recently, an investigation of outcomes in 1815 patients across 7 US centers conducted by the IGNITE network demonstrated that CYP2C19 IM/PMs prescribed clopidogrel had a 2.26-fold higher risk for MACCE after PCI compared with those that prescribed alternative therapy. 19 Our results, and those of the IGNITE study, are consistent with retrospective genetic analyses that have repeatedly demonstrated higher risk for MACCE in CYP2C19 IM/PMs treated with clopidogrel after PCI. [6] [7] [8] It is important to note that 572 of the 868 genotyped patients in our single-center analysis were included in the multicenter IGNITE network investigation. The current study extends those results, shows no difference in clinically significant bleeding across genotypes, and demonstrates that the fidelity in which CYP2C19-guided antiplatelet therapy is applied in practice can vary significantly over time. Our results are also consistent with 3 international prospective studies, which demonstrated that CYP2C19 genotypeguided intensification of antiplatelet therapy in IMs and PMs significantly reduced MACCE compared with conventional therapy without genotyping and did not increase risk for bleeding. [20] [21] [22] Collectively, these studies provide an expanding evidence base demonstrating that genotype-guided selection of DAPT after PCI is associated with lower rates of MACCE without any increase in clinically significant bleeding. An ongoing randomized controlled clinical trial will assess the utility of CYP2C19-guided antiplatelet therapy in a prospective fashion in ≈5000 patients undergoing PCI, but will not be completed until 2020 (URL: https://www.clinicaltrials.gov. Unique identifier: NCT01742117).
The American College of Cardiology Foundation/ American Heart Association PCI guidelines state that genetic testing and use of alternative therapy in genetically predisposed nonresponders might be considered in high-risk patients (Class IIb, Level of Evidence: C). 1 The Food and Drug Administration black box warning in the clopidogrel label specifically warns prescribers of reduced clopidogrel effectiveness in PMs. 16, 17 The majority (20 of 24) of PMs at our institution received alternative therapy and virtually all (17 of 18) MACCE events observed in IM/PMs treated with clopidogrel occurred in IMs. These data are consistent with the IGNITE network results, 19 demonstrate that the elevated risk of adverse cardiovascular outcomes is not limited to PMs, and support the Clinical Pharmacogenetics Implementation Consortium recommendation to use alternative therapy in CYP2C19 IMs and PMs if CYP2C19 genotype is known. 5 Furthermore, the elevated risk of MACCE in CYP2C19 IM/PMs prescribed clopidogrel was most evident in patients that underwent PCI for an ACS indication, which is consistent with the multicenter IGNITE network results. 19 These data are also consistent with prior retrospective analyses that have demonstrated the strongest associations between CYP2C19 LOF alleles and risk of MACCE occur in higher risk strata of patients prescribed clopidogrel, such as PCI versus non-PCI and ACS versus non-ACS indications. 9, 28 Collectively, our results suggest that (1) clinicians need to be aware of the risks associated with use of clopidogrel in CYP2C19 IMs and PMs, and (2) genotype-guided selection of antiplatelet therapy, with use of alternative therapy in CYP2C19 IMs and PMs, should be considered in high-risk patients undergoing PCI. Because of the low number of events, the clinical impact of genotyping in patients undergoing PCI for a non-ACS indication remains unclear and will require further study.
We observed that clinical factors indicative of high risk for future cardiovascular events, including an ACS indication for PCI and placement of a left anterior descending or left main artery stent, were the strongest predictors of genotype testing during the index PCI admission. These findings illustrate that the interventional cardiologist's decision to genotype is reactive after risk stratification, consistent with the algorithm. CYP2C19 phenotype was the strongest predictor of antiplatelet therapy selection, indicating that CYP2C19 genotype was frequently used to guide the prescribing decision when available. However, clinical factors such as an ACS indication for PCI, risk factors for bleeding, and prior P2Y 12 inhibitor use on admission were also significantly associated with DAPT selection. Moreover, the presence of risk factors for bleeding significantly modified the association between the CYP2C19 result and medication selection. These data illustrate that, although important, the genotype result is one of the multiple factors considered when selecting DAPT in a real-world setting, and clinicians may be reluctant to prescribe alternative therapy in IM/PMs with risk factors for bleeding. However, the significantly lower risk of MACCE observed in CYP2C19 IM/PMs prescribed alternative therapy compared with clopidogrel was not offset by a higher risk of bleeding events, which were similar across CYP2C19 phenotype and DAPT groups and consistent with other recent prospective studies. [20] [21] [22] These data suggest that the ischemic risk conferred by clopidogrel use in IM/PMs may outweigh the risk for clinically significant bleeding events conferred by alternative therapy and that placing greater weight on a CYP2C19 IM/PM result during the prescribing decision may be warranted in certain cases.
Although the feasibility of clinically implementing genotype-guided antiplatelet therapy has been demonstrated, 23, 26, 29, 30 the sustainability of obtaining, interpreting, and using CYP2C19 genotype to guide P2Y 12 inhibitor selection over time has not been investigated. We observed a high overall frequency of CYP2C19 testing (73% of all PCI patients; 81% Figure 3 Continued. alternative therapy (LOF-alt), ultrarapid, rapid or normal metabolizers without a LOF allele prescribed clopidogrel (No LOF-clop); patients without a LOF prescribed alternative therapy (No LOF-alt). The unadjusted log-rank P value for outcomes across the 4 groups, and the adjusted hazard ratio (HR), 95% confidence interval (CI) and P value for the indicated between-group comparisons, are provided.
of ACS patients) and use of alternative therapy in CYP2C19 IM/PMs (71% of all PCI patients; 78% of ACS patients). The feasible implementation and sustainable use of a genotype-guided algorithm at our institution was possible because of several key factors that alleviated logistical barriers. Notably, in-house genotype testing with prompt turnaround of results in the EHR, and interdisciplinary collaboration and communication among physicians, clinical pharmacists, and nurses have proven critical. Indeed, pharmacists are essential to the successful application of pharmacogenomics in clinical practice. 31 Despite the high overall use of genotype-guided antiplatelet therapy, we also observed that the proportion of PCI patients genotyped and IM/PMs prescribed alternative therapy significantly varied over time. The latter appeared driven by a significant decline in IM/PMs that underwent a change from clopidogrel to alternative therapy. These results demonstrate that implementation of an algorithm that uses genetic testing to guide drug selection is difficult to sustain at a high level in clinical practice. Because evaluation of barriers to sustained implementation via provider surveys was beyond the scope of the current study, it remains unclear what specific factors contributed to the observed fluctuations in fidelity. Although recurrent clinician education was employed, automated clinical decision support (CDS) within the EHR to alert clinicians about the genotype result was not available at our institution during the study period. Clinician education and clinical decision support have been proposed as key solutions to facilitate fidelity, sustainability, and scale of genotype-guided prescribing within and across sites. 32 Future studies are needed to evaluate the direct benefits of these strategies to overcome key implementation barriers. The costs associated with CYP2C19 genetic testing are also an important consideration. Recent cost-effectiveness analyses have estimated a per patient cost of $100 to 350, and the Centers for Medicare and Medicaid Services 2017 Clinical Laboratory Fee Schedule reports a reimbursement amount of $293 for CYP2C19 testing. 33, 34 These studies have collectively concluded that, from a third-party payer's perspective, CYP2C19 genotype-guided antiplatelet therapy after PCI may be a cost-effective strategy over both a 1-year and lifetime horizon when compared with either universal clopidogrel or universal prasugrel or ticagrelor treatment without genotype testing. 33 The short-term cost-effectiveness of a genotype-guided strategy over the first 30 days after PCI has also been recently described. 34 However, these analyses have been limited by their use of clinical outcome data derived from retrospective genetic analyses of registries and clinical trials. Future studies are needed to evaluate the cost-effectiveness of implementing CYP2C19 genotype-guided antiplatelet therapy from the health system perspective using clinical outcome and cost data derived from real-world clinical practice.
It is important to acknowledge several limitations with our study. First, data collection was completed retrospectively via EHR abstraction. Although retrospective data collection minimized influence on the practice under evaluation, we were unable to conclusively determine whether clopidogrel use in IM/PMs was a conscious clinical decision or failure to acknowledge the genotyping result. Second, genotype-guided therapy was not randomized. Thus, we cannot exclude the influence of bias or attribute cause and effect to the observed associations between CYP2C19 phenotype, DAPT selection, and outcomes. To lessen the potential confounding effects related to differences across groups, covariate-adjusted and stratified analysis were conducted; however, residual confounding may remain and the magnitude of the observed association between clopidogrel use in IM/PMs and risk of MACCE should be interpreted with caution. Third, the analysis is based on medications prescribed, but there is no available data on adherence. Last, the data presented reflects the experience with genotypeguided antiplatelet therapy at a single academic medical center, and the results may not be generalizable to other settings and populations. Future studies in larger and more diverse populations are warranted.
CONCLUSIONS
The adverse cardiovascular outcomes associated with clopidogrel use in patients with a CYP2C19 LOF allele suggest that the use of genotype-guided antiplatelet therapy in practice may significantly improve clinical outcomes. Given the increasing number of institutions that seek to clinically implement genotype-guided antiplatelet therapy, [23] [24] [25] our results offer insight into the feasibility, sustainability, and clinical impact of using a CYP2C19 genotyping strategy to optimize P2Y 12 inhibitor selection in PCI patients.
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